CONCLUSIONS CONFLICTS OF INTEREST In the last 5 years Adie Viljoen has received lecture honoraria and/or travel support and/or conducts clinical trials funded by: Amarin, Amgen, Astra Zeneca, Boehringer Ingleheim, Daiichi-Sankyo, Lilly, Menarini, NewAmsterdam, Novartis, Novo Nordisk, Pfizer, Regeneron, Sanofi, Takeda, and Tosoh
Various oxidative stress markers, including lipid peroxide [80], malondialdehyde [133], a marker of oxidative DNA damage 8-hydroxy-2-deoxyguanosine [119], and protein carbonyls [134, 135] are increased in ASD children
With samples available for R&D purposes, we support generic companies to be first to file
GLP-1based therapies share several common adverse effects and carry some rare but important risks
Their clinical impact has since expanded dramatically due to their ability to induce sustained weight loss, improve insulin sensitivity, reduce systemic inflammation, and alter gut physiology